血管内皮生长因子与抗肿瘤研究进展  

Research Advance in Vascular Endothelial Growth Factor and Anti-Tumor

作　　者：李振华[1] 崔为发[1] 刘世超[1] 

机构地区：[1]潍坊医学院附属医院,山东潍坊261042

出　　处：《现代诊断与治疗》2008年第3期161-164,共4页Modern Diagnosis and Treatment

摘　　要：血管内皮生长因子(VEGF)在实体瘤的发生、发展及转移过程中起重要作用,并且是实体瘤预后的一项独立指标。恶性肿瘤细胞亦高水平表达VEGF,且与肿瘤血管新生密切相关,VEGF还作用于肿瘤细胞表面特异性受体,促进肿瘤细胞增殖,阻止肿瘤细胞凋亡,也是恶性肿瘤独立的预后指标。抗新生血管治疗的靶点是新生的肿瘤血管,以VEGF及其受体(VEGFR)为靶向的血管新生抑制药物的研发,得到了广泛的重视。随着抑制肿瘤新生血管的基础研究、临床试验技术和其他相关技术的不断发展,抑制肿瘤新生血管的药物开发和临床应用会达到更成熟的阶段。Vascular endothelial growth factor（VEGF） plays an important role in the process of incidence,development and transfer of solid tumors,and is an independent indicator of the prognosis of solid tumors.Cancer cells have a high level expression of VEGF,which is closely related to tumor angiogenesis.VEGF also acts in tumor-specific cell surface receptors to promote the proliferation of tumor cells and prevent apoptosis of tumor cells,which is an independent prognostic indicator of malignant tumors.Tumor angiogenesis is the new target of anti-angiogenesis therapy.The research and development of angiogenesis inhibition drug targeting VEGF and VGFR has received broad attention.Along with the continuing development of basic research,clinical laboratory technique and other related technology of inhibition of tumor angiogenesis,the drug research and clinical application of inhibition of tumor angiogenesis will reach a mature stage.

关 键 词：血管内皮生长因子 肿瘤 治疗 进展 

分 类 号：R730.54[医药卫生—肿瘤]